• Bookmarks
    • Add bookmark
  • Login
  • About Us
  • Investigators
    • Dra. Ibane Abasolo Olaortua
    • Dr. Diego Arango del Corro
    • Dra. Gemma Ariceta Iraola
    • Dra. Eva Baldrich Rubio
    • Dra. Coro Bescós Atin
    • Dr. Joan Castell Conesa
    • Dra. Mari Carmen Domínguez Luengo
    • Dr. Manuel Galiñanes Hernández
    • Dr. José Raúl Herance
    • Dr. Joan López Hellín
    • Dr. Mario Marotta Baleriola
    • Dr. Vicenç Martínez Ibáñez
    • Dra. Anna Meseguer Navarro
    • Dr. Victor Puntes
    • Dr. Joan Sayós Ortega
    • Dr. Simó Schwartz Jr
  • Research Groups
    • Biomedical Research in Digestive Tumors
    • Drug Delivery and Targeting
    • Immune Regulation and Immunotherapy Group
    • Kidney Physiopathology
    • Diagnostic Nanotools for Fast Assay and Biosensor Development.
    • New Technologies and Craniofacial Microsurgery
    • Pharmacokinetic Nanoparticles
    • Reparative Therapy of the Heart
    • The Bioengineering, Cell Therapy and Surgery in Congenital Malformations (Bio-Cell Fetal)
    • Medical Molecular Imaging
  • Preclinical Services
    • In Vitro Experimental Platform
    • In Vivo Experimental Platform
    • Rates & Services
    • Mission, Vision and Quality Policy Statement of FVPR
    • Other services
  • Publications
  • Highlights
  • Contact
Close
  • About Us
  • Investigators
    • Dra. Ibane Abasolo Olaortua
    • Dr. Diego Arango del Corro
    • Dra. Gemma Ariceta Iraola
    • Dra. Eva Baldrich Rubio
    • Dra. Coro Bescós Atin
    • Dr. Joan Castell Conesa
    • Dra. Mari Carmen Domínguez Luengo
    • Dr. Manuel Galiñanes Hernández
    • Dr. José Raúl Herance
    • Dr. Joan López Hellín
    • Dr. Mario Marotta Baleriola
    • Dr. Vicenç Martínez Ibáñez
    • Dra. Anna Meseguer Navarro
    • Dr. Victor Puntes
    • Dr. Joan Sayós Ortega
    • Dr. Simó Schwartz Jr
  • Research Groups
    • Biomedical Research in Digestive Tumors
    • Drug Delivery and Targeting
    • Immune Regulation and Immunotherapy Group
    • Kidney Physiopathology
    • Diagnostic Nanotools for Fast Assay and Biosensor Development.
    • New Technologies and Craniofacial Microsurgery
    • Pharmacokinetic Nanoparticles
    • Reparative Therapy of the Heart
    • The Bioengineering, Cell Therapy and Surgery in Congenital Malformations (Bio-Cell Fetal)
    • Medical Molecular Imaging
  • Preclinical Services
    • In Vitro Experimental Platform
    • In Vivo Experimental Platform
    • Rates & Services
    • Mission, Vision and Quality Policy Statement of FVPR
    • Other services
  • Publications
  • Highlights
  • Contact

Biomedical Research in Digestive Tumors

HomeBlogBiomedical Research in Digestive Tumors

The EMA designates a new orphan drug for Fanconi anemia in whose development VHIR has participated

21 November, 2018 573
The EMA designates a new orphan drug for Fanconi anemia in whose development VHIR has participated

The European Commission, upon proposal from the European Medicines Agency (EMA), has designated Gefitinib as an orphan drug for Fanconi anemia. This orally administered product is currently indicated for the treatment of lung cancer. The studies...

Read more

Three VHIR researchers receive three important European grants

22 December, 2015 1398
Three VHIR researchers receive three important European grants

Dr. Simó Schwartz Jr, head of the CIBBIM-Nanomedicine Drug Delivery and Targeting group, Dr. Diego Arango, head of the CIBBIM-Nanomedicine Biomedical Research in Digestive Tumors group, and Dr. Mar Hernández-Guillamón, principal investigator of...

Read more

VHIR receives two grants from the AECC to investigate stomach cancer and melanoma

25 September, 2015 1085
VHIR receives two grants from the AECC to investigate stomach cancer and melanoma

The Vall d’Hebron Research Institute (VHIR) has received two projects in the last call of the Associación Española Contra el Cáncer (AECC) to investigate stomach cancer and malignant melanoma. The projects, worth 1,200,000 euros each, are...

Read more

VHIR researchers validate a new therapeutic target for colorectal cancer treatment

9 September, 2015 1098
VHIR researchers validate a new therapeutic target for colorectal cancer treatment

Researchers from the Group of Molecular Oncology CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR) have validated a gene, called PPOX, as a new therapeutic target against colorectal cancer. Furthermore, this study opens the door...

Read more
Search
Categories
  • About-us
  • Biomedical Research in Digestive Tumors
  • Drug Delivery and Targeting
  • events
  • Immune Regulation and Immunotherapy Group
  • Kidney Physiopathology
  • New Technologies and Craniofacial Microsurgery
  • News
  • Pharmacokinetic Nanoparticles
  • Publications
  • The Bioengineering, Cell Therapy and Surgery in Congenital Malformations (Bio-Cell Fetal)
  • Uncategorized
Recent Posts
Tres investigadores del VHIR reciben una beca de la Asociación Española Contra el Cáncer
Tres investigadores del VHIR reciben una beca de la Asociación Española Contra el Cáncer
8 days agoby CIBBIM - Nanomedicine0
Cerium oxide nanoparticles may improve hepatocellular carcinoma prognosis
Cerium oxide nanoparticles may improve hepatocellular carcinoma prognosis
24 February, 2020by CIBBIM - Nanomedicine0
Tags
CLINICAL APPLICATION OF NANOMEDICINE ESNAM EUROPEAN SOCIETY FOR NANOMEDICINE INTERNATIONAL SOCIETY OF NANOMEDICINE ISN
Contact Us
CIBBIM-Nanomedicine
Institut de Recerca
Hospital Universitari Vall d'Hebron
Passeig Vall d'Hebron, 119-129-
08035 Barcelona - Spain
Tel: +34 93 489 4055
Fax: +34 93 489 4040
  • Email: info@cibbim.eu


CIBBIM-Nanomedicine laboratories are located within VHIR’s premises (Mediterrània and Collserola buildings, in violet), Bus lines and Metro stations (Line Green (L3); stops of Montbau and Vall d’Hebron) are also indicated.

ACCESS MAP LOCAL
Albertino © 2014 All Rights Reserved
Forgot password?
You can login using your social profile
Problem with login?
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More